FGF21 and metabolic dysfunction-associated steatotic liver disease: High level of circulating FGF‐21 as well as elevated hepatic FGF‐21 mRNA expression have been reported in obesity, type 2 diabetes and NAFLD in both animal models and human subjects 52, 53, 54, 55, 62, 63, 64, 65.